NCT01154088View on ClinicalTrials.gov

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds

PHASE3CompletedINTERVENTIONAL
Enrollment

1,170

Participants

Timeline

Start Date

August 27, 2010

Primary Completion Date

December 30, 2010

Study Completion Date

December 30, 2010

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Mencevax ACWY

One dose, Subcutaneous injection

BIOLOGICAL

GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]

One dose, Intramuscular injection

Trial Locations (3)

10400

GSK Investigational Site, Bangkok

Unknown

GSK Investigational Site, Panama City

GSK Investigational Site, City of Muntinlupa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01154088 - Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds | Biotech Hunter | Biotech Hunter